Maximus Posts 77 Percent Increase in EBITDA, Sustaining Upward Trend; Revenue Soars by 63 Percent

New Delhi [India], November 26: Maximus reported a 63% rise in revenue to INR 751 Mn and a 77% increase in EBITDA for HYE ’24, driven by consistent growth and strategic initiatives. PAT grew by 62% to INR 43 Mn, reflecting robust profitability. A successful capital raise of INR 211.48 Mn supported investments in subsidiaries, debt reduction, and working capital, strengthening the company’s financial position and growth trajectory.

Update on Financial Performance

  • Sustained Revenue Progress: The company posted revenue of INR 751 Mn for the first half of the year, marking a significant 63% growth compared to HYE ’23. This increase reflects consistent performance and sustained quarter-on-quarter progress.
  • EBITDA Expansion: Driven by consistent growth, the company clocked EBITDA of INR 73 Mn during HYE ’24, a notable 77% increase from HYE ’23. This achievement also signifies an 83% jump over Q2 ’23 and a 12% rise from Q1 ’24, showcasing strong momentum.
  • Strategic Excellence: The impressive results underscore the company’s strategic focus and commitment to maintaining healthy EBITDA margins over multiple quarters.
  • Accelerated Profit Growth: The rise in EBITDA has propelled PAT to INR 43 Mn, reflecting a 62% increase from HYE ’23. The PAT level has been sustained at the same as QE June ’24, illustrating stable financial leverage.
  • Strengthened Leverage Position: The company has improved its financial health with a 39% reduction in its debt-equity ratio from HYE ’23 and enhanced its Interest Service Coverage Ratio, emphasising financial resilience.

Update on Fundraising

  • Successful Capital Raise: The company successfully raised INR 211.48 Mn through the issuance of 103.16 lakh shares at INR 20.50 per share on a preferential basis.
  • Strategic Investments in Subsidiaries: A significant portion of approximately INR 85.50 Mn was strategically invested in subsidiaries, focusing on the Kenyan manufacturing unit to upgrade its facilities, machinery, and infrastructure and to meet increased working capital demands linked to the East African expansion. This investment is expected to enhance production capacity, support growing local market needs, and facilitate expansion into neighboring countries, including Tanzania and Uganda.
  • Debt Optimization and Working Capital Support: Around INR 68 Mn has been earmarked to bolster working capital and reduce debt, thereby optimising finance costs and improving leverage. The company has allocated funds in line with the disclosures in the financial statement notes, positioning itself for sustainable growth and improved profitability.

Financial Synopsis: 

Figures in INR Mn.

Particular Half Yearly
Sep-24 Sep-23 Change %
Revenue 751 460 63%
EBIDTA 73 41 77%
PBT 50 26 93%
PAT 43 26 62%
D/E Ratio 0.63 1.03 39%
Interest Service Coverage Ratio 4.93 4.60 7%

 

aayush jain acquisition Business cashew processing cote d’ivoire esos 2026 pacific global fzco Pajson Agro pulkit jain Royal Mewa Share Swap

From Local to Global: Pajson Agro India to Acquire Pacific Global FZCO, Adding 60,000 MT Capacity at the World’s Largest Cashew Origin

All-stock 100% acquisition | ₹354.52 crore | Board also approves ESOS 2026 New Delhi [India], November 6: Pajson Agro India Limited (PAJSON | 544657 | INE14LM01012), a vertically integrated cashew processing company with farm-gate sourcing across key producing origins and a growing consumer brand, ‘Royal Mewa’, has announced that its Board of Directors, has approved […]

Read More
Business Fredun Pharmaceuticals EBITDA Growth Fredun Pharmaceuticals H1 FY27 Results Fredun Pharmaceuticals Net Profit Fredun Pharmaceuticals Revenue Growth Indian pharmaceutical industry

Fredun Pharmaceuticals On A Growth Overdrive: Net Profit Soars 94%, Ebitda Rockets 92% And Revenue Surges 87% In H1 Fy27

Mumbai (Maharashtra) [India], November 6: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), one of India’s leading pharmaceutical formulation manufacturing companies, has announced its unaudited financial results for Q2 & H1 FY27. The Company offers a diversified portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products. Key Financial Highlights Standalone key Financial Highlights […]

Read More
Business

Patil Automation Marks a Strong First Half of FY27; Consolidated Revenue Up 37% YoY, Net Profit Up 48%

Mumbai (Maharashtra) [India], November 6: Patil Automation Limited (NSE: PATILAUTOM | INE17GV01016), a leading provider of turnkey welding, assembly and robotics-integrated automation solutions, has released its Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2026, reporting broad-based growth across the group. Performance Snapshot – H1 FY27 H1 FY27 Key Financial […]

Read More